Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.

• Status: Active, not recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Burn pain is known to be one the most severe forms of acute pain often requiring large amounts of narcotics in addition to other adjuvants. Topical lidocaine is effective for controlling pain in various settings including dressing changes of burns. The aim of this study is to demonstrate the effectiveness of topical lidocaine in decreasing pain scores and narcotic requirements when applied to donor graft sites while at the same time not interfering with the standard of care TheraBond dressing. During this study the investiagtors will be monitoring for evidence of delayed wound healing, and surgical site infection.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Florida
• Treatments: Epinephrine; Epinephryl borate; Lidocaine; Pharmaceutical Solutions; Racepinephrine

Criteria

Inclusion Criteria:

• Adult patients who have suffered second to third degree burns requiring a single split thickness skin graft surgery.

• Donor sites will be between 3-15% TBSA.

Exclusion Criteria:

• Patients who have history of chronic pain,

• opioid abuse history,

• major renal and/or liver dysfunction,

• history of seizures or major neurologic deficiencies,

• allergy to local anesthetics,

• reported allergy to hydromorphone,

• pregnancy, or

• currently have other injuries that significantly contribute to pain (i.e. multi-trauma patients) will be excluded from the study.